Charles River Labs Intl Stock
Price
Target price
€136.95
€136.95
-1.240%
-1.65
-1.240%
€165.88
18.03.26 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
A loss of -1.240% shows a downward development for Charles River Labs Intl.
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
With a target price of 165 € there is a positive potential of 20.48% for Charles River Labs Intl compared to the current price of 136.95 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | -1.240% | -10.226% | 0.514% | -15.306% | -20.678% | -24.295% | -43.409% |
| United Therapeutics | -1.860% | -1.659% | 13.581% | 61.038% | 8.238% | 123.107% | 223.427% |
| Iovance Biotherapeutics Inc. | -2.940% | -19.517% | 44.973% | 2.335% | 41.336% | -44.715% | -87.177% |
| Ligand Pharmaceuticals | -0.550% | 0.000% | 13.665% | 83.000% | 10.241% | 191.773% | 40.607% |
Comments
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "buy" rating reaffirmed by analysts at TD Cowen.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International (NYSE:CRL) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Show more
Ratings data for CRL provided by MarketBeat